Skip to Content
Global News Select

CytoSorbents Gets Second FDA Breakthrough Device Designation for DrugSorb-ATR

By Colin Kellaher


CytoSorbents Corp. on Thursday said the U.S. Food and Drug Administration granted a second breakthrough-device designation for its DrugSorb-ATR antithrombotic removal system.

The Monmouth Junction, N.J., provider of blood-purification technology said the new designation covers the removal of the direct oral anticoagulants apixaban and rivaroxaban in a cardiopulmonary bypass circuit to reduce the likelihood of serious perioperative bleeding in urgent cardiothoracic surgery.

The FDA last year granted breakthrough designation to DrugSorb-ATR to remove ticagrelor for the same application.

The FDA's breakthrough-devices program aims to expedite the development and review of technology that offers significant advantages over existing approved products.

Shares of CytoSorbents, which closed Wednesday at $7.80, rose more than 15% in premarket trading Thursday.


Write to Colin Kellaher at


(END) Dow Jones Newswires

August 12, 2021 08:27 ET (12:27 GMT)

Copyright (c) 2021 Dow Jones & Company, Inc.